文献速递消化系统肿瘤

胰腺导管腺癌术后复发导向治疗的生存获益:荷兰国家队列与美国机构队列的倾向性评分匹配分析

Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dutch National and US institutional cohort.
PubMed 文献 · Eur J Cancer · 2026-10-09

该观察性队列纳入2014-2022年荷兰所有胰腺手术中心及NYU Langone Health的PDAC切除后局部或远处复发患者1423例,采用倾向性评分匹配比较复发导向治疗(RFT)与仅最佳支持治疗(BSC)的复发后生存(PRS)。匹配后344对患者中,RFT组中位PRS为10个月(95%CI 9-12),BSC组为4个月(95%CI 3-4),校正HR 0.38(95%CI 0.30-0.48,P<0.001);预后较差与较好亚组均显示RFT与更长PRS相关。

要点

  • PDAC切除后复发患者接受RFT较仅BSC显著延长PRS。
  • 匹配后RFT组中位PRS 10个月,BSC组4个月,校正HR 0.38。
  • 预后较差与较好亚组中RFT均与更长PRS相关。

核心结论

  • PDAC复发后治疗与仅BSC相比与显著更长的PRS相关,且与复发时预后无关。
  • RFT相关的生存获益支持在PDAC复发患者管理中考虑RFT。

研究设计与样本

  • 观察性队列研究,纳入2014-2022年荷兰所有胰腺手术中心及NYU Langone Health的PDAC切除后局部或远处复发患者。
  • 排除RFT或生存状态未知者,共纳入1423例患者。
  • 采用既往建立的PRS风险评分将复发时预后分为较差(≥174.5)与较好(<174.5)亚组。
  • 在总体队列及亚组内进行倾向性评分匹配(PSM),匹配后344例RFT患者与344例仅BSC患者配对。
  • 采用Kaplan-Meier曲线和log-rank检验比较中位PRS,多变量Cox回归以匹配对为聚类稳健标准误校正PSM后残余不平衡,结果以HR和95%CI表示。

主要发现

  • 匹配后总体队列RFT组中位PRS为10个月(95%CI 9-12),仅BSC组为4个月(95%CI 3-4),校正HR 0.38(95%CI 0.30-0.48,P<0.001)。
  • 预后较差亚组RFT组中位PRS为10个月(95%CI 9-11),仅BSC组为3个月(95%CI 3-4),校正HR 0.38(95%CI 0.30-0.50,P<0.001)。
  • 预后较好亚组RFT组中位PRS为18个月(95%CI 12-27),仅BSC组为8个月(95%CI 4-14),校正HR 0.24(95%CI 0.10-0.45,P<0.001)。

关键数值与推荐

  • 复发时预后采用既往建立的PRS风险评分定义,较差亚组为评分≥174.5,较好亚组为评分<174.5。
  • 多变量分析纳入ECOG体能评分及国家作为随机效应。

临床怎么用

  • PDAC切除后复发患者可考虑复发导向治疗,而非仅给予最佳支持治疗。
  • 复发时预后较差或较好的患者均可能从RFT中获得PRS延长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unclear whether recurrence-focused treatment (RFT) improves survival in all patients with recurrent pancreatic ductal adenocarcinoma (PDAC). This study aimed (1) to evaluate post-recurrence survival (PRS) in patients treated with RFT versus best supportive care (BSC)-only, and (2) to assess potential effect modification by prognosis at recurrence. METHODS: This observational cohort study included patients with local or distant recurrence after PDAC resection (2014-2022) at all Dutch pancreatic surgery centers and NYU Langone Health. Patients with unknown RFT or survival status were excluded. Prognosis at recurrence was defined using a previously established PRS risk score, stratifying patients into worse (≥174.5) and better (<174.5) prognostic subgroups. Propensity score matching (PSM) was performed in the overall cohort, and within subgroups. Median PRS in RFT versus BSC-only patients was estimated and compared using Kaplan-Meier curve analysis and the log-rank test. Multivariable Cox regression with robust standard errors clustered by matched pair was used to adjust for residual imbalance after PSM, with results presented as hazard ratios (HR) and 95% confidence intervals (95%CI). RESULTS: Overall, 1423 patients were included. After PSM, 344 RFT patients were matched to 344 BSC-only patients. The multivariable analysis included ECOG performance score and country as a random effect. PRS was 10 (95%CI 9-12) months for RFT versus 4 (95%CI 3-4) months for BSC-only (adjusted HR0.38, 95%CI: 0.30-0.48, P < 0.001). In the worse prognosis group, PRS was 10 (95%CI 9-11) versus 3 (95%CI 3-4) months (adjusted HR0.38, 95%CI: 0.30-0.50, P < 0.001). In the better prognosis group, PRS was 18 (95%CI 12-27) months versus 8 (95%CI 4-14) months (adjusted HR0.24, 95%CI: 0.10-0.45, P < 0.001). CONCLUSIONS: Treatment for PDAC recurrence was associated with significantly longer PRS compared with BSC-only, irrespective of prognosis at recurrence. The survival benefit associated with RFT supports its consideration in the management of patients with PDAC recurrence.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Andel PCM, van Oosten AF, van Goor IWJM, et al. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dutch National and US institutional cohort. Eur J Cancer. 2026. PMID: 42869861. doi:10.1016/j.ejca.2026.117776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。